Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PFE crawled time : 01:00 save search
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
Published: 2024-03-06 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 3.14%
H: 1.49%
C: 1.08%
KZR | $0.8016 -2.95% -3.04% 420K
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: -1.9%
financial results
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.29%
H: 0.38%
C: -0.14%
velsipity active
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
Published: 2023-10-27 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.32%
H: 0.23%
C: -3.06%
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 2.58%
H: 0.08%
C: -3.42%
nefecon conference kidney presentation chinese week
Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth
Published: 2023-10-03 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.29%
H: 0.8%
C: 0.18%
fda rare report global growth market
Everest Medicines Announces Interim Results for First Half of 2023
Published: 2023-08-24 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.5%
H: 0.45%
C: -0.86%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.27%
H: 1.15%
C: -1.19%
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -4.72%
H: 0.0%
C: 0.0%
results
Global Hemophilia Research Analysis Report 2023: A $21.07 Billion Market by 2030 - Approval of Gene Therapies and Monoclonal Antibodies Fueling Growth
Published: 2023-08-16 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.46%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.71%
H: 1.45%
C: 0.97%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.3%
H: 1.35%
C: 0.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
report approval research global growth market
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.95%
H: 0.19%
C: -0.32%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.19%
H: 0.11%
C: -1.46%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.32%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.03%
H: 0.12%
C: -0.24%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: 0.13%
report business cancer treat global
Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit
Published: 2023-04-26 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.43%
H: 0.08%
C: -1.35%
pharma business
Global Peptide Antibiotics Market Report 2022: Sector to Reach $5.74 Billion in 2026 at a CAGR of 8%
Published: 2023-03-28 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.05%
H: 0.25%
C: -0.52%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.38%
H: 1.25%
C: 1.12%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.17%
C: -0.09%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.36%
H: 0.9%
C: 0.55%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
report antibiotics global market
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
Published: 2022-12-22 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda ema ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-30 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.87%
H: 0.98%
C: -1.43%
trial potential positive results topline license phase 3 ulcerative colitis
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
Published: 2022-01-19 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.32%
H: 1.57%
C: -0.21%
stone-302 treatment ema ces cel lung cancer cancer
Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors
Published: 2021-11-03 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.07%
H: 1.03%
C: -1.54%
solid tumors trial xin
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
Published: 2021-05-13 (Crawled : 01:00) - achievelifesciences.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.35%
H: 0.2%
C: -0.55%
ACHV | $4.53 0.67% 0.66% 32K
|
Health Technology
|
| O: 3.22%
H: 8.07%
C: 1.29%
financial results results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.